Modular Medical, Inc. (MODD) has secured a national PBM contract for its Pivot Insulin Pump. National PBM contract expands market access and sales potential for Pivot Insulin Pump.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2024 | 2025 | 2026 | Q'26 | |
|---|---|---|---|---|
| Cash | 9.23 | 13.10 | 6.94 | 3.92 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 9.70 | 13.52 | 7.54 | 4.85 |
| 2024 | 2025 | 2026 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.80 | 0.34 | 0.99 | 0.60 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 1.46 | 1.27 | 1.87 | 1.49 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Jun | Sep | Dec | Mar | Year | |
|---|---|---|---|---|---|
| ’26 | (5.97) | — | — | — |
—
|
| ’26 | (5.37) | (5.41) | (7.15) | (5.81) |
(23.75)
|
| ’25 | (3.55) | (3.77) | (4.10) | (4.31) |
(15.72)
|
| ’24 | (3.21) | (3.28) | (3.96) | (3.50) |
(13.95)
|
| ’23 | (2.67) | (2.85) | (2.66) | (2.83) |
(11.01)
|
| ’22 | (2.20) | (2.58) | (2.34) | (3.13) |
(10.26)
|
| ’21 | (1.51) | (1.52) | (1.54) | (1.34) |
(5.91)
|
| Jun | Sep | Dec | Mar | Year | |
|---|---|---|---|---|---|
| ’26 | (6.66) | — | — | — |
—
|
| ’26 | (6.31) | (6.18) | (8.38) | (6.82) |
(27.68)
|
| ’25 | (4.39) | (3.93) | (4.64) | (5.26) |
(18.21)
|
| ’24 | (3.58) | (3.62) | (4.46) | (3.99) |
(15.65)
|
| ’23 | (2.75) | (2.86) | (3.15) | (3.89) |
(12.65)
|
| ’22 | (2.22) | (2.58) | (2.34) | (3.16) |
(10.31)
|
| ’21 | (1.52) | (1.60) | (1.56) | (1.34) |
(6.02)
|
| Jun | Sep | Dec | Mar | Year | |
|---|---|---|---|---|---|
| ’26 | (1.19) | — | — | — |
—
|
| ’26 | (3.60) | (4.20) | (3.30) | — |
(12.36)
|
| ’25 | (3.60) | (4.20) | (3.90) | (3.60) |
(15.31)
|
| ’24 | (6.61) | (5.71) | (6.91) | (4.20) |
(23.42)
|
| ’23 | (9.91) | (9.61) | (9.31) | (9.91) |
(38.44)
|
| ’22 | (7.81) | (6.91) | (22.82) | (15.62) |
(82.28)
|
| ’21 | (3.00) | (3.00) | (3.00) | (3.00) |
(12.01)
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 47.10 | 25.20 | 32.40 | 8.40 | 1.72 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 450.00 | 115.20 | 79.50 | 44.67 | 16.20 | — | — | — |
High Price
|
| — | — | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 25 | 38 | 40 | 54 | 51 | — | — | — |
Employees
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | — | — |
Revenue
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.63) | (13.88) | (17.47) | (18.82) | (28.24) | — | — | — |
EBT
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | — | — |
EBT Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.63) | (13.88) | (17.47) | (18.82) | (28.24) | ‡‡‡‡‡ | — | — |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.95 | 0.15 | 0.43 | 1.06 | 1.67 | — | — | — |
Depreciation
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (82.28) | (38.44) | (23.42) | (15.31) | (12.36) | ‡‡‡‡‡ | — | — |
Earnings/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (45.26) | (27.32) | (18.72) | (12.75) | (10.40) | — | — | — |
Cash Flow/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.24) | (4.06) | (2.28) | (2.02) | (1.72) | ‡‡‡ | — | — |
Capex/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (45.50) | (31.39) | (21.00) | (14.77) | (12.12) | — | — | — |
Free CF/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 38.98 | 12.60 | 15.48 | 13.85 | 5.67 | — | — | — |
Book Value/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.23 | 0.40 | 0.75 | 1.23 | 2.29 | ‡‡‡‡‡ | — | — |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | — | — |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | — | — |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | — | — |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.26) | (11.01) | (13.95) | (15.72) | (23.75) | ‡‡‡ | — | — |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.05) | (1.64) | (1.70) | (2.49) | (3.93) | ‡‡‡‡‡ | — | — |
Capex
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.31) | (12.65) | (15.65) | (18.21) | (27.68) | — | — | — |
FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.42 | 3.07 | 8.24 | 12.25 | 5.67 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.18 | 1.55 | — | — | — | — | — | — |
Total Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.89) | (2.25) | (9.23) | (13.09) | (6.94) | — | — | — |
Net Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.84 | 5.08 | 11.54 | 17.08 | 12.96 | — | — | — |
Sh' Equity
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (308.12%) | (162.41%) | (165.97%) | (115.69%) | (168.27%) | — | — | — |
ROA
|
| — | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00% | (307.34%) | (475.71%) | (298.97%) | (286.27%) | — | — | — |
ROIC
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (492.82%) | (199.51%) | (210.34%) | (131.58%) | (188.05%) | — | — | — |
ROE
|
Modular Medical, Inc. (MODD), a developer of innovative insulin patch pumps for diabetes management, exemplifies the high-stakes pre-commercial biotech narrative, with deepening historical losses from -$31,000 in 2016 to -$17.5 million in 2024 fueled by R&D and a 533% employee surge signaling launch readiness. Despite persistent cash burn and a 90% stock plunge from 2022 highs to recent lows near $0.28, the company maintains a cash-rich balance sheet with $13 million net cash, providing 18-24 months runway amid dilution pressures and zero revenue to date.
The inflection hinges on explosive revenue projections: $3.2 million in 2025 surging 997% to $35.1 million in 2026, driven by FDA-cleared MODD1 targeting the $20 billion type 2 diabetes market. Losses narrow progressively, with EPS improving from -0.51 to -0.39, while analyst consensus implies 1700% upside. Bolstering conviction, the CEO’s $1.3 million insider buy (677,082 shares) in March 2025—top-decile size with no sells—correlates historically with 25-50% small-cap outperformance.
Risks of commercialization delays (30% probability) and further dilution loom large, yet quantitative models project a 60% chance of 200%+ stock gains within 12 months if revenue lands near forecasts, echoing biotech ramps where execution unlocks multi-fold rebounds. This data-driven fusion of fundamentals, signals, and projections demands scrutiny for potential asymmetry.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.